[
  {
    "ts": "2025-10-23T22:51:00+00:00",
    "headline": "Dividend Stocks Aren’t Just for Income Investors. Here’s Another Reason to Buy Them.",
    "summary": "Investors use dividend-paying funds for portfolio diversification, viewing these companies as more trustworthy and better capital stewards.",
    "url": "https://www.barrons.com/articles/dividend-stocks-buy-income-investing-46818922?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "b67c126c-a63b-315d-9c8f-159d8cce8456",
      "content": {
        "id": "b67c126c-a63b-315d-9c8f-159d8cce8456",
        "contentType": "STORY",
        "title": "Dividend Stocks Aren’t Just for Income Investors. Here’s Another Reason to Buy Them.",
        "description": "",
        "summary": "Investors use dividend-paying funds for portfolio diversification, viewing these companies as more trustworthy and better capital stewards.",
        "pubDate": "2025-10-23T22:51:00Z",
        "displayTime": "2025-10-23T22:51:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/b67c126c-a63b-315d-9c8f-159d8cce8456/dividend-stocks-aren%E2%80%99t-just.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/3ebb436db35697fd857f025de0312dad",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eP4b4XRmwob6OMPQwd66Kg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/3ebb436db35697fd857f025de0312dad.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DleG8lSom3d2ZBt.NITznw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/3ebb436db35697fd857f025de0312dad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/dividend-stocks-buy-income-investing-46818922?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "UPS"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "SCHD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T16:53:32+00:00",
    "headline": "Roche in ongoing discussions with US government over drug pricing, CEO says",
    "summary": "US pricing pressures come amid aggressive deal-making moves by Roche to bolster its internal pipeline.",
    "url": "https://www.pharmaceutical-technology.com/news/roche-in-ongoing-discussions-with-us-government-over-drug-pricing-ceo-says/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "e127d13d-0607-3e4f-a53d-b1beaabc8e7d",
      "content": {
        "id": "e127d13d-0607-3e4f-a53d-b1beaabc8e7d",
        "contentType": "STORY",
        "title": "Roche in ongoing discussions with US government over drug pricing, CEO says",
        "description": "",
        "summary": "US pricing pressures come amid aggressive deal-making moves by Roche to bolster its internal pipeline.",
        "pubDate": "2025-10-23T16:53:32Z",
        "displayTime": "2025-10-23T16:53:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/891f9a9e737ba58ae25fc27cbcd63614",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fSnrAK6XAGzOuCY6mbcBrA--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/891f9a9e737ba58ae25fc27cbcd63614.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jJsralfKiDjm7hqGsJhxkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/891f9a9e737ba58ae25fc27cbcd63614.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/roche-in-ongoing-discussions-with-us-government-over-drug-pricing-ceo-says/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/roche-ongoing-discussions-us-government-165332078.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN.L"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T15:15:00+00:00",
    "headline": "Medpace Holdings’ Good Quarter Is Another Sign Biotech Is Back",
    "summary": "The strong earnings report from  Medpace Holdings  which runs clinical trials to test biotech companies’ new drugs, offers more evidence that the biotech sector is on the rebound.  Medpace said late Wednesday that it had $789 million in new orders in the third quarter, up about 49% from the year-ago period.  Its clinical trial backlog was up 2.5% from the 2024 third quarter, signaling an improving environment for the small- and midsize biotechs that make up most of its clients.",
    "url": "https://www.barrons.com/articles/medpace-holdings-earnings-biotech-stock-price-fddb1efa?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "e3e8dc52-578d-3c42-ac96-7a3c70ef9308",
      "content": {
        "id": "e3e8dc52-578d-3c42-ac96-7a3c70ef9308",
        "contentType": "STORY",
        "title": "Medpace Holdings’ Good Quarter Is Another Sign Biotech Is Back",
        "description": "",
        "summary": "The strong earnings report from  Medpace Holdings  which runs clinical trials to test biotech companies’ new drugs, offers more evidence that the biotech sector is on the rebound.  Medpace said late Wednesday that it had $789 million in new orders in the third quarter, up about 49% from the year-ago period.  Its clinical trial backlog was up 2.5% from the 2024 third quarter, signaling an improving environment for the small- and midsize biotechs that make up most of its clients.",
        "pubDate": "2025-10-23T15:15:00Z",
        "displayTime": "2025-10-23T15:15:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e3e8dc52-578d-3c42-ac96-7a3c70ef9308/medpace-holdings%E2%80%99-good.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/7a03ddd95560a3b112731c346cd3ee81",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yhh4J0IUkPek838W0VbfMA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/7a03ddd95560a3b112731c346cd3ee81.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/senZJniJFZgt_dJezUa74A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/7a03ddd95560a3b112731c346cd3ee81.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/medpace-holdings-earnings-biotech-stock-price-fddb1efa?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ICLR"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "XBI"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MEDP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T14:39:00+00:00",
    "headline": "Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?",
    "summary": "Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.",
    "url": "https://finance.yahoo.com/news/lilly-10-month-buy-sell-143900884.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1ec8677d-8d39-301b-a5d6-d50edf5cd483",
      "content": {
        "id": "1ec8677d-8d39-301b-a5d6-d50edf5cd483",
        "contentType": "STORY",
        "title": "Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?",
        "description": "",
        "summary": "Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.",
        "pubDate": "2025-10-23T14:39:00Z",
        "displayTime": "2025-10-23T14:39:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A9LQHlDmqgPJbKsotfjd8w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5.ym16dSp_UIlCHMRMZUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-10-month-buy-sell-143900884.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-10-month-buy-sell-143900884.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T09:38:00+00:00",
    "headline": "United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall",
    "summary": "The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving this growth include an aging population, heightened smoking rates, and environmental influences. The demand for innovative inhalers, biologics, and rehabilitation programs is rising. Key segments include chronic bronchitis and emphysema, with treatment options spanning drugs, oxygen therapy, and surgery. States l",
    "url": "https://finance.yahoo.com/news/united-states-chronic-obstructive-pulmonary-093800023.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "3c48a395-c319-30f3-b321-4961b6b2de07",
      "content": {
        "id": "3c48a395-c319-30f3-b321-4961b6b2de07",
        "contentType": "STORY",
        "title": "United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall",
        "description": "",
        "summary": "The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving this growth include an aging population, heightened smoking rates, and environmental influences. The demand for innovative inhalers, biologics, and rehabilitation programs is rising. Key segments include chronic bronchitis and emphysema, with treatment options spanning drugs, oxygen therapy, and surgery. States l",
        "pubDate": "2025-10-23T09:38:00Z",
        "displayTime": "2025-10-23T09:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/056daae854c02d87f5354dc46353aa05",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "U.S. Chronic Obstructive Pulmonary Disease (COPD) Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t4uV.9YjYRS5sH0lun3FNw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/056daae854c02d87f5354dc46353aa05.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/v6zRKa81BDY.Qv2Ile1qNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/056daae854c02d87f5354dc46353aa05.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/united-states-chronic-obstructive-pulmonary-093800023.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/united-states-chronic-obstructive-pulmonary-093800023.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "4503.T"
            },
            {
              "symbol": "ABT"
            },
            {
              "symbol": "ALM.MC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T09:24:00+00:00",
    "headline": "Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue",
    "summary": "The pharma group lifted its guidance citing strong results to date, and reported a rise in sales excluding currency movements.",
    "url": "https://www.wsj.com/health/pharma/roche-raises-full-year-earnings-outlook-a682a191?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "aa304ba4-27e4-3473-b9ad-6750e8d5f729",
      "content": {
        "id": "aa304ba4-27e4-3473-b9ad-6750e8d5f729",
        "contentType": "STORY",
        "title": "Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue",
        "description": "",
        "summary": "The pharma group lifted its guidance citing strong results to date, and reported a rise in sales excluding currency movements.",
        "pubDate": "2025-10-23T09:24:00Z",
        "displayTime": "2025-10-23T09:24:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/aa304ba4-27e4-3473-b9ad-6750e8d5f729/roche-raises-full-year.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/ad8c2606b4ddc1f62ef297586c7fe14d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dBCNLYSunnVUvHeOzvug0Q--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/ad8c2606b4ddc1f62ef297586c7fe14d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MStmAxNectmoLAKAnZ7mwQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/ad8c2606b4ddc1f62ef297586c7fe14d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/roche-raises-full-year-earnings-outlook-a682a191?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN.L"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]